Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Pagel BioPharma: The research summary related to CR059 has been accepted by the American Diabetes Association 2026 Scientific Sessions and selected as a latest breakthrough abstract
Pagel BioPharma Announcement: The research summary related to the company’s independently developed innovative candidate product CR059 has been accepted by the American Diabetes Association (ADA) 2026 Scientific Sessions and selected as a Late Breaking Abstract, to be presented in poster format. The abstract shows that CR059 demonstrates significant weight loss effects, outstanding blood sugar reduction performance, and long-term expression characteristics, with the potential for monthly dosing, and even extended to quarterly dosing, supporting sustained expression and long-acting metabolic control.